Healthcare Biotech Facts & Figures

19.08.2011

Healthcare Biotech Facts & Figures 

From diagnosis to treatment and in terms of medicines manufactured, healthcare biotechnology is already delivering on its promises:

  • More than 325 million patients have benefited from approved medicines manufactured through biotechnology and gene technology to treat or prevent heart attacks, stroke, multiple sclerosis, breast cancer, cystic fibrosis, leukemia, hepatitis, diabetes and other diseases.
  • Today, 418 new biotech medicines and vaccines are being tested for more than 100 diseases, among which 210 to treat cancer, 50 to treat infectious diseases and 44 to treat autoimmune disorders. Biotech medicines are estimated to account for approximately 20% of all marketed medicines and represent 50% of all medicines in the pipeline.
  • The industry in Europe comprises some 1,600 companies and represented revenues of approximately € 7.8 billion in 2005.
  • Increasingly, diagnostic test kits and diagnostic services are using biotech methods and reagents.
  • For the first time in the history of human healthcare, biotechnology is enabling the development and/or manufacturing of therapies for a number of rare diseases with a genetic origin. Although individually rare, collectively these diseases affect some 20 to 30 million Europeans and their families, with 70-80% having a genetic component requiring biotechnology as part of the solution.
  • Biotechnology is also increasingly used in healthcare research, in combination with medical devices and surgical methods.
  • Biotechnology has a major impact on the provision of safe and effective vaccines against infectious diseases.
  • Biotechnology also provides safe recombinant alternatives to proteins derived from human blood or tissue.

Biotech medicines

  • Biotech companies focusing on healthcare biotech rose from 37 (1996) to 143 (2005). 
  • 78% of EU biotech products are biotech medicines. 
  • Biotech medicines hold a 9% share of the EU pharmaceutical market.
  • Growth rates in biopharmaceuticals are twice as high as non-biotech.

Biotech offers healthcare:

  • unique therapeutic and diagnostic solutions; 
  • unlimited supplies of potentially safer products; 
  • superior therapeutic and diagnostic approaches.

EU Commission's study: "Consequences, opportunities & challenges of biotech in Europe" (March 2007)